Stock Track | TransMedics Group Soars 6.56% in Pre-market on Strong Q4 Results, Upbeat Guidance and Analyst Upgrades

Stock Track02-25

TransMedics Group, Inc. (TMDX) saw its stock price soar 6.56% in pre-market trading on Wednesday.

The surge follows the company's release of strong fourth-quarter and full-year 2025 financial results after the previous trading session. TransMedics reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. The medical technology company also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth.

Adding to the positive sentiment, multiple analysts raised their price targets on the stock in pre-market activity. Needham increased its target price to $174 from $166, while JP Morgan raised its target to $149 from $114. Needham also maintained its Buy rating on the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133777085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 20:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133777085","market":"nz","top_or_hot":-1,"title":"Stock Track | TransMedics Group Soars 6.56% in Pre-market on Strong Q4 Results, Upbeat Guidance and Analyst Upgrades","media":"Stock Track","content":"<p>TransMedics Group, Inc. (TMDX) saw its stock price soar 6.56% in pre-market trading on Wednesday.</p><p>The surge follows the company's release of strong fourth-quarter and full-year 2025 financial results after the previous trading session. TransMedics reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. The medical technology company also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth.</p><p>Adding to the positive sentiment, multiple analysts raised their price targets on the stock in pre-market activity. Needham increased its target price to $174 from $166, while JP Morgan raised its target to $149 from $114. Needham also maintained its Buy rating on the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TransMedics Group Soars 6.56% in Pre-market on Strong Q4 Results, Upbeat Guidance and Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TransMedics Group Soars 6.56% in Pre-market on Strong Q4 Results, Upbeat Guidance and Analyst Upgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-25 20:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TransMedics Group, Inc. (TMDX) saw its stock price soar 6.56% in pre-market trading on Wednesday.</p><p>The surge follows the company's release of strong fourth-quarter and full-year 2025 financial results after the previous trading session. TransMedics reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. The medical technology company also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth.</p><p>Adding to the positive sentiment, multiple analysts raised their price targets on the stock in pre-market activity. Needham increased its target price to $174 from $166, while JP Morgan raised its target to $149 from $114. Needham also maintained its Buy rating on the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMDX","symbol_name":"Transmedics Group","start_time":0,"source_url":"","article_id":"1133777085","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133777085","pubTimestamp":1772022166,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TransMedics Group, Inc. (TMDX) saw its stock price soar 6.56% in pre-market trading on Wednesday.The surge follows the company's release of strong fourth-quarter and full-year 2025 financial results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TMDX":"Transmedics Group"},"translate_title":"个股追踪|TransMedics Group盘前飙升6.56%，得益于强劲的Q4业绩、乐观的指引和分析师升级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":1},"content_text":"TransMedics Group, Inc. (TMDX) saw its stock price soar 6.56% in pre-market trading on Wednesday.The surge follows the company's release of strong fourth-quarter and full-year 2025 financial results after the previous trading session. TransMedics reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. The medical technology company also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth.Adding to the positive sentiment, multiple analysts raised their price targets on the stock in pre-market activity. Needham increased its target price to $174 from $166, while JP Morgan raised its target to $149 from $114. Needham also maintained its Buy rating on the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133777085","isCrawlerRequest":true}